Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $4.03 million. The enterprise value is -$1.73 million.
| Market Cap | 4.03M |
| Enterprise Value | -1.73M |
Important Dates
The last earnings date was Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 3.95 million shares outstanding.
| Current Share Class | 3.95M |
| Shares Outstanding | 3.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +3,468.28% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 7.38% |
| Float | 3.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.24 |
| Forward PS | n/a |
| PB Ratio | 0.29 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.21 |
| Quick Ratio | 2.04 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.72 |
Financial Efficiency
Return on equity (ROE) is -105.23% and return on invested capital (ROIC) is -33.93%.
| Return on Equity (ROE) | -105.23% |
| Return on Assets (ROA) | -27.03% |
| Return on Invested Capital (ROIC) | -33.93% |
| Return on Capital Employed (ROCE) | -57.02% |
| Weighted Average Cost of Capital (WACC) | 23.95% |
| Revenue Per Employee | $322,912 |
| Profits Per Employee | -$5.10M |
| Employee Count | 2 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.70 |
Taxes
In the past 12 months, Onconetix has paid $525 in taxes.
| Income Tax | 525 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.31% in the last 52 weeks. The beta is 2.68, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 2.68 |
| 52-Week Price Change | -99.31% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 33.97 |
| Relative Strength Index (RSI) | 65.60 |
| Average Volume (20 Days) | 461,573 |
Short Selling Information
The latest short interest is 152,101, so 3.85% of the outstanding shares have been sold short.
| Short Interest | 152,101 |
| Short Previous Month | 196,172 |
| Short % of Shares Out | 3.85% |
| Short % of Float | 3.85% |
| Short Ratio (days to cover) | 0.54 |
Income Statement
In the last 12 months, Onconetix had revenue of $645,824 and -$10.20 million in losses. Loss per share was -$17.16.
| Revenue | 645,824 |
| Gross Profit | 519,226 |
| Operating Income | -7.69M |
| Pretax Income | -10.20M |
| Net Income | -10.20M |
| EBITDA | -7.67M |
| EBIT | -7.69M |
| Loss Per Share | -$17.16 |
Balance Sheet
The company has $5.94 million in cash and $187,128 in debt, with a net cash position of $5.76 million or $1.46 per share.
| Cash & Cash Equivalents | 5.94M |
| Total Debt | 187,128 |
| Net Cash | 5.76M |
| Net Cash Per Share | $1.46 |
| Equity (Book Value) | 13.47M |
| Book Value Per Share | 3.55 |
| Working Capital | 3.57M |
Cash Flow
| Operating Cash Flow | -10.31M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 14,753 |
| Net Borrowing | -4.56M |
| Free Cash Flow | -10.31M |
| FCF Per Share | -$2.61 |
Margins
| Gross Margin | 80.40% |
| Operating Margin | -1,190.29% |
| Pretax Margin | -1,578.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Onconetix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -253.13% |
| FCF Yield | -255.90% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 53.91% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Onconetix has an Altman Z-Score of -12.46 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.46 |
| Piotroski F-Score | 3 |